Disruptive precision medicine technology conquering inflammation and diabetes
Mission, Vision and Values
BTI develops safer and more effective nutritionals and therapeutics for autoimmune and metabolic diseases.
BTI strives to create personalized nutritionals, therapeutics and informatics solutions that transform healthcare.
Integrity, Passion, Creativity, Innovation, Teamwork.
Biotherapeutics Inc. (BTI) is a science-based biotechnology company that integrates nutraceuticals, pharmaceuticals and informatics to advance precision medicine for preventing and treating autoimmune and metabolic diseases.
Dr. Josep Bassaganya-Riera, Virginia Tech professor and director of the university’s Nutritional Immunology and Molecular Medicine Laboratory (NIMML), recognized the impact his lab’s innovative research could have on public health, but he lacked the vehicle to take it from research to product. Joining with others in 2008, he formed Biotherapeutics Inc. BTI soon demonstrated the value of the university-industry link by developing BT-11, an orally active, first-in-class therapeutic for Crohn’s Disease (CD) and abscisic acid (ABA), a food ingredient for glycemic control. New products are in the pipeline.